InVivo Therapeutics Holdings Corp. (NVIV) announced today that
Thomas Ulich, M.D., Chief Scientific Officer, will present at the annual
Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held
October 7-9 at the Estancia La Jolla Hotel in La Jolla, CA. The
company’s presentation will be on Wednesday, October 7 at 11:00 AM
(PDT). A live webcast will be available at http://stemcellmeetingonthemesa.com/webcast/.
Co-hosted by the Alliance for Regenerative Medicine (ARM), the
California Institute for Regenerative Medicine (CIRM), and the Sanford
Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the
Mesa is a three-day conference featuring the program’s two-day
Partnering Forum, the Public Forum lecture, and a full-day scientific
symposium.
Stem Cell Meeting on the Mesa is expected to attract nearly 800
attendees, including leading cell therapy, gene therapy, and tissue
engineering companies, large pharma and biotech, industry investors, and
major academic research institutions.
Dr. Ulich said, "For several years now, InVivo Research has focused on
the development of a novel treatment paradigm for chronic spinal cord
injury patients, namely, the delivery of neural stem cells capable of
neuronal differentiation on a bio-resorbable scaffold. This meeting will
allow us to meet with other leaders in the field as we advance toward
the clinic."
About the Neuro-Spinal Scaffold™
Following an acute spinal cord injury, the biodegradable Neuro-Spinal
Scaffold is surgically implanted at the epicenter of the wound and
is designed to act as a physical substrate for nerve sprouting.
Appositional healing to spare spinal cord tissue, decreased
post-traumatic cyst formation, and decreased spinal cord tissue pressure
have been demonstrated in preclinical models of spinal cord contusion
injury. The Neuro-Spinal Scaffold, an investigational device, has
received a Humanitarian Use Device (HUD) designation and is currently
being studied in an Investigational Device Exemption (IDE) pilot study
for the treatment of patients with complete (AIS A) traumatic acute
spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold received the 2015
Becker’s Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. These statements can be
identified by words such as "believe," "anticipate," "intend,"
"estimate," "will," "may," "should," "expect,"
“designed to,” “potentially,” and similar expressions, and include
statements regarding the expected benefits, efficacy and future clinical
timelines of the company’s Neuro-Spinal Scaffold and the impact on the
company of increased exposure within the scientific and medical
community. Any forward-looking statements contained herein are based on
current expectations, and are subject to a number of risks and
uncertainties. Factors that could cause actual future results to differ
materially from current expectations include, but are not limited to,
risks and uncertainties relating to the company’s ability to
successfully open additional clinical sites for enrollment and to enroll
additional patients; the timing of the Institutional Review Board
process; the company’s ability to obtain FDA approval to modify its
pilot trial protocol or to conduct a future study; the company’s ability
to commercialize its products; the company’s ability to develop, market
and sell products based on its technology; the expected benefits and
efficacy of the company’s products and technology in connection with the
treatment of spinal cord injuries; the availability of substantial
additional funding for the company to continue its operations and to
conduct research and development, clinical studies and future product
commercialization; and other risks associated with the company’s
business, research, product development, regulatory approval, marketing
and distribution plans and strategies identified and described in more
detail in the company’s Annual Report on Form 10-K for the year ended
December 31, 2014, and its other filings with the SEC, including the
company’s Form 10-Qs and current reports on Form 8-K. The company does
not undertake to update these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150929005744/en/
Copyright Business Wire 2015